Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19911638 | 0.80 | GRM2 (0.50) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL30036706 | 0.78 | SLC9A1 (0.50) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL256210 | 0.78 | SLC9A1 (0.50) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL19911637 | 0.76 | GRM2 (0.62) | SLC9A1KEAP1GRM2 | |
| SCHEMBL19848410 | 0.76 | SLC9A1 (0.48) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL18186933 | 0.76 | GRM2 (0.50) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL10734042 | 0.76 | SLC9A1 (0.48) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL30929215 | 0.76 | GRM2 (0.62) | SLC9A1KEAP1GRM2 | |
| SCHEMBL31474375 | 0.76 | SLC9A1 (0.48) | SLC9A1KEAP1KDM4ELMNATSHR | |
| SCHEMBL9134619 | 0.74 | SLC9A1 (0.47) | SLC9A1KEAP1KDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2336131-A1 | Hydantoin compounds | Eisai R&D Management Co., Ltd. (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20100113446-A1 | HYDANTOIN COMPOUNDS | GALLAGHER JR BRIAN M | 2010-05-06 | — | — | US | disclosed |
| US-7666875-B2 | 1,3,8-triazaspiro(4,5)decane derivatives; antiinflammatory agent for treating rheumatoid arthritis, allergic, multiple sclerosis, autoimmune disease such as inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-1888583-A2 | HYDANTOIN COMPOUNDS | Eisai Co., Ltd. (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20060270696-A1 | Hydantoin compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| WO-2006128143-A2 | HYDANTOIN COMPOUNDS | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270696-A1 | Hydantoin compounds | HNMT, HLA-DRB1, SSB | SLC9A1 101/4885KEAP1 610/4885KDM4E 1585/4885 |
| US-20100113446-A1 | HYDANTOIN COMPOUNDS | HNMT, HLA-DRB1, SSB | SLC9A1 101/4885KEAP1 610/4885KDM4E 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.